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Abstract  
Objective: Probiotic are beneficial microbial nutrition supplements which have useful effects on human 
health by conserving of bowel microbial balance. There are many studies that have been recommended the use 
of probiotic products as cancer risk reducer. The aim of present study was to investigate antimutagenic 
potential of Probiotic Lactobacillus sporogenes against TA98 and TA100 strain of Salmonella typhimurium.  
Material and Methods: Ames test was used in the present investigation to evaluate antimutagenic activity in 
TA98 and TA100 strains of Salmonella typhimurium using direct acting mutagens (Sodium azide) and 
different concentration of Probiotic L.Sporogenes (25, 50, 100 and 500 μg/0.1 ml/plate).  
Results: Probiotic Lactobacillus sporogenes showed significant anti-mutagenicity against mutagen sodium 
azide in TA98 and TA100 tester strains whereas it showed anti-mutagenicity result in inhibition of 93-97% and 
62-88% of his+ revertants induced by sodium azide in TA98 and TA100 strains respectively. 
Conclusion: The anti-mutagenicity of Probiotic Lactobacillus sporogenes the observed in the present study 
implies chemopreventive pharmacological importance of Probiotic Lactobacillus sporogenes and encourages 
its use as a biotherapeutic agent. 
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Introduction 
Cancer is one of the most significant deaths causing in the world [1]. Cancer can take over 200 different 
forms, including lung, prostate, breast, ovarian, hematologic, skin, and colon cancer, and leukemia, and 
both environmental factors (tobacco smoke, alcohol, radiation, and chemicals) and genetic factors 
(inherited mutations and autoimmune dysfunction) are associated with an increased risk of developing 
cancer. Bacterial and viral infections are also strongly associated with some types of cancer (stomach 
cancers and cervical cancer, respectively). The enormous numbers and diversity of the human gut 
microflora is reflected in a large and varied metabolic capacity, particularly in relation to xenobiotic 
biotransformation, carcinogen synthesis and activation. The metabolic activities of the gut microflora can 
have wide ranging implications for the health of the host, resulting in both beneficial and detrimental 
effects [2]. 
Probiotics are defined as viable microorganisms that have beneficial health of a host [3].
 
They are 
considered to be ‘‘Generally Recognized as Safe’’ (GRAS) and used for different applications in food 
 
[4]. 
They have been used for therapeutic purposes like replenish the normal gut flora [5].
 
 
Probiotics have been of scientific and commercial interest due to a range of health promoting attributes, 
including suppression of growth of pathogens, control of cholesterol levels, immune system modulation, 
improvement of lactose digestion, vitamin synthesis, increased bioavailability of minerals and possible 
anticarcinogenic activity 
 
[6-9]. 
Anti-genotoxicity and anti-mutagenicity are now frequently included among the functional properties for 
characterizing probiotic microorganisms [10, 11].
 
 
The probiotics recommended for human applications are primarily two classes of lactic acid producing 
microorganisms: the bifidobacteria and lactic acid bacteria (LAB) including species of Enterococcus, 
Lactobacillus, Lactococcus, Leuconostoc, Pediococcus and Streptococcus [12, 13]. Some yeast strains such 
as Saccharomyces cerevisiae and Saccharomyces boulardii have also emerged as probiotics for their 
influence on the human intestinal flora [14-16].  
During recent years, probiotics have received considerable attention as dietary agents to modify the gut 
microflora and hence potentially modulate cancer risk [17]. 
Lactobacillus sporogenes are stable under the extreme conditions of heat, acid and bile salt conditions.
 
[1] Due to their stability, strains of Lactobacillus sporogenes survive through gastro intestinal condition of 
host and exhibit beneficial effects [18].
 
 
The aim of present study was to investigate anti-mutagenic potential of probiotic Lactobacillus 
sporogenes against mutagen sodium azide in TA98 and TA100 strain of Salmonella typhimurium by using 
Ames test.  
Materials and methods 
Probiotic strain 
Probiotic strain of Lactobacillus sporogenes were procured from Unique Biotech Limited, Unit-II, 
Hyderabad, India 
Chemicals and Reagents  
Sodium azide (SA), Dimethyl sulfoxide, Histidine, biotin, Magnesium sulfate, citric acid monohydrate, 
potassium phosphate dibasic anhydrous, sodium ammonium phosphate, dextrose, Agar, sodium chloride. 
All chemicals employed in the studies were of analytical reagent grade. 
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Bacterial strains 
Clinical strains of two human pathogenic bacteria of Gram-negative bacteria Salmonella typhimurium 
TA98 (MTCC 1251) and Salmonella typhimurium TA100 (MTCC 1252) were used for the Ames assay. All 
the microorganisms were obtained from the Institute of microbial technology (IMTECH), Chandigarh and 
maintained in the Department of Pharmaceutical Microbiology, SSR College of Pharmacy, Silvassa. A fresh 
nutrient broth culture was grown to a density of 1-2 × 10
9
 cells/ml for 12 hour at 37°C before each 
experiment.  
Determination of antimutagenicity against direct acting mutagens 
Salmonella mutagenicity assay was conceded out as previously described by Mortelmans K and Zeiger E, 
2000 [19].
 
Plate incorporation method was done for anti-mutagenicity assay without microsomal activation. 
Fresh bacterial cultures of S. typhimurium strains TA 100 and TA 98 (1-2 ×10
9
cells/ml) were mixed with 
2ml of molten agar containing 0.5 mm histidine/biotin solution, different concentration of L.Sporogenes (25, 
50, 100 and 500 μg/0.1 ml/plate) and direct acting mutagens such as sodium azide (2.5μg/plate). Further it 
was spread over minimal glucose agar plates. Plates were incubated for 48 hours at 37ºC and the revertant 
colonies were counted. Steps involved in the plate incorporation method depicted in the Figure 1.
 
Figure 1 Schematic representation of Steps involved in the plate incorporation method 
 
Percent inhibition of mutagenicity was determined by the following formula:  
 
 /         .
 %   
 /    
1 100
His revertant induced plate by mutagen in the presence of probiotic L Sporogenes
Inhibition of mutagenicity
His revertant induced plate by mutagen alone


  
Statistical analysis 
Results were expressed as Mean ± S.E.M. Statistical significance was tested using one way ANOVA as 
appropriate using computer based fitting program (GraphpadPrism 6.0.). Differences were considered to be 
statistically significant when p < 0.05. 
Results and Discussions 
Antimutagenic activity of Probiotic L.Sporogenes against TA98 and TA100 strain of 
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Salmonella typhimurium 
In the present investigation, different doses of L.Sporogenes (LS) was selected for evaluation purpose LS 25, 
LS 50, LS 100 and LS 500 groups were given 25 μg, 50 μg, 100 μg and 500 μg per plate respectively. 
Sodium azide (SA) serves as positive control.  
Evaluation of anti-mutagenic potential of Probiotic strain L.sporogenes was demonstrated by colony 
characteristic using Ames test against Salmonella typhimurium TA98 (MTCC 1251) and Salmonella 
typhimurium TA100 (MTCC 1252) as shown in figure 2 a) and b), respectively. 
 
 
 
 
(a) 
 
 
 
 
(b) 
Figure 2 Evaluation of anti-mutagenic potential of Probiotic strain L.sporogenes using (a) Salmonella 
typhimurium TA98 (MTCC 1251) (b) Salmonella typhimurium TA100 (MTCC 1252) 
 
Experimental Results of anti-mutagenic studies (given in Table 1) revealed that culture of L.Sporogenes 
was effective in reducing the mutagenicity caused by the mutagen (sodium azide). 
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Table 1 In vitro Anti-mutagenic activity of Lactobacillus sporogenes against sodium azide on Salmonella 
typhimurium strain TA 98 and TA 100. 
n=3 Trial, ***p<0.001 extremely significant, **p<0.01 very significant, *p<0.05 significant, nsp>0.05 
nonsignificant, significant compared to positive control, values are expressed as Mean±SEM. 
 
The percent inhibition of sodium azide induced mutagenicity was recorded as 93.14±1.58, 94.1±1.05, 
95.97±1.40, and 97.43±0.06 in TA 98 and 63.75±2.57, 75.42±0.93, 76.61±0.64, 88.37±0.80 in TA100 for 
dose 25, 50, 100,and 500 μg/plate respectively (Table 1). Antimutagenic activity of L.Sporogenes in 
Salmonella typhimurium TA98 (MTCC 1251) and TA100 (MTCC 1252) against sodium azide was shown 
in figure 3 (a) and (b), respectively. 
 
 
(a) (b)                 
                                       
Figure 3 Anti-mutagenic activity L.Sporogenes in (a) Salmonella typhimurium TA98 (MTCC 1251) (b) 
Salmonella typhimurium TA100 (MTCC 1252) against sodium azide. There was a statistically significant 
difference (p<0.001) at all dose level with respect to control and among L.sporogenes when analyzing the data 
by One Way ANOVA. 
 
As is clear from figure 3 (a) and (b), a dose dependent response was observed with maximum percentage 
inhibition obtained at maximum dose of L.Sporogenes tested.  
According to one way ANOVA the protective effect of L.Sporogenes against SA induced mutagenicity in 
Treatment 
Dose 
(μg/plate) 
TA 98 TA 100 
 
Number of his+ 
revertant/plate 
% Inhibition 
Number of his
+ 
revertant/plate 
% Inhibition 
Positive Control SA 817±7.33 --- 765±47.4 --- 
Co-incubation 
(SA + LS) 
25 56± 4.27** 93.14±1.58** 285.3±42.74** 62.75±2.57** 
50 48±2.07** 94.1±1.05** 188±13.3** 75.42±0.93** 
100 33±3.12** 95.97±1.40** 156.3±8.373** 79.61±0.64** 
500 21±4.41** 97.43±0.06** 89.67±15.59** 88.37±0.80** 
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TA 98 and TA 100 was verified and found significant (p < 0.05). 
In the present study, the Ames test is a basic toxological test that can be used to determine if a substance 
is potentially genotoxic. Ames test serves as a quickest way to analyze the carcinogenic potential of a 
compound. It is a very easy and cheap test that can be set up in most labs. In this test Salmonella 
typhimurium strains carrying mutations in the histidine operon is being used, hence are histidine dependent. 
Mutagens are agents (physical or environmental) that can induce a genetic mutation or the increase in rate 
of mutation whereas antimutagens are agents that inhibit the effects of mutagens. Addition of mutagens, 
bacteria reverse back to histidine independent and form colonies in histidine deficient medium. So addition 
of anti-mutagenic agents considerably reduces reverse mutation capability of mutagens. 
Different bacterial strains used here detect different mutagens. TA 100 detect mutagens causing base pair 
substitutions, TA 98 detects frame shift mutagen.  
Mutagens may be either direct acting or requiring microsomal activation. Direct acting mutagens interact 
directly with DNA to produce mutation. In this study direct acting mutagens like Sodium azide, were used 
and able to reverse the mutation of bacteria to form colonies in minimal glucose agar plates. 
Sodium azide on positive plate shown maximum growth and the auxotrophic strain of Salmonella 
typhimurium showed back mutation and converted to its wild type average growth was found on negative 
control plate which was without addition of sodium azide. 
A preventive effect on malignant development could be mediated by production of anti-mutagens and 
LAB binding of mutagens, and this has been reviewed [20]. One possible mechanism for the 
anti-mutagenic properties of LAB involves a physical binding of the mutagenic compounds by these 
bacteria. In a review of the therapeutic role of dietary LAB, Fernandes et al [21]. suggested that the cellular 
uptake of nitrites by LAB reduced the formation of nitrosamines from nitrites. In vitro assessment of 
possible antimutagenic actions of LAB, specifically L. casei and a blend of B. longum and L. gasseri, 
indicated a significant reduction in mutagen induced chromosome aberrations and micronuclei [22]. In a 
study with healthy adults, consumption of fermented milk containing L. acidophilus (~10
10
-10
11
 cfu) 
contributed to a significant decline in mutagenic activity in the urine and feces following three days of 
supplementation 
 
[23]. 
In general, live cells of probiotic bacteria showed higher anti-mutagenic activity, and this was permanent, 
in contrast to killed cells. In this in vitro study, butyric acid, and to a lesser extent, acetic acid inhibited 
mutagens. Strains of B. lactis were shown to express anti-mutagenic properties, probably linked to cell wall 
constituents. The anti-mutagenic effect was active also after acid and bile treatment, mimicking the GI 
transport, and interestingly, enhanced in the presence of whole milk [24].
 
One mechanism for this effect can 
be binding of mutagens, and heterocyclic aromatic amines were shown to be bound to the cell wall of 
certain bacteria, such as B. longum and other LAB, and thereby be detoxified [25, 26]. In L. plantarum 
KLAB21, however, the anti-mutagenic effect was mediated by three glycoproteins which are secreted 
extracellularly [27].  
Conclusion 
The results showed that most significant inhibition of mutagenicity induced to TA 98 by the direct acting 
mutagens such as sodium azide. The anti-mutagenicity of probiotic Lactobacillus sporogenes the observed 
in the present study implies chemopreventive pharmacological importance of probiotic Lactobacillus 
sporogenes and encourages its use as a Biotherapeutic agent. 
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